Redeye: Xvivo Perfusion - High Activity Ahead

Sales of consumables in Q1 were in line with our forecast, but total sales beat our estimates due to higher-than-expected sales of durable goods. We foresee a high activity in the coming 12 months, with the initiation of the next clinical trial with PrimECC in Q3 and a larger trial in the heart indication in early 2019.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.